Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease
- PMID: 12176170
- DOI: 10.1016/s0006-8993(02)02934-7
Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease
Abstract
Trophic effects of neurturin, a member of the glial cell line-derived neurotrophic factor-family, have been demonstrated on mesencephalic dopaminergic neurons, suggesting its therapeutic potential for Parkinson's disease. This study was designed to test the neuroprotective and regenerative effects of an intrastriatal injection of neurturin based on behavioral, neurochemical and histochemical changes in a rat model of progressive Parkinson's disease. An extensive and progressive dopaminergic lesion was unilaterally made by intrastriatal convection-enhanced delivery of 6-hydroxydopamine (6-OHDA), in which 20 microg of 6-OHDA dissolved in 20 microl of vehicle was infused at a rate of 0.2 microl/min. For neuroprotection study, recombinant human neurturin (5 microg in 5 microl of vehicle) was stereotaxically injected into the unilateral striatum. The 6-OHDA lesion was made on the ipsilateral side 3 days after the neurturin treatment. Tyrosine hydroxylase (TH)-immunoreactive neurons of the substantia nigra were protected from progressive degeneration in the neurturin-treated animals compared with the vehicle-treated animals 2 and 8 weeks after the 6-OHDA lesion. Eight weeks after the 6-OHDA lesion, dopamine concentration significantly increased in the striatum of neurturin-treated animals with improvement of methamphetamine-induced rotation behavior. For neuroregeneration study, 5 microg of neurturin was injected into the striatum 12 weeks after the 6-OHDA lesion. Four weeks after neurturin or vehicle injection, there were no significant differences in the survival of nigral TH-immunoreactive neurons between the groups. However, TH-immunoreactive fibers were thicker and more abundant in the striatum of the neurturin-treated rats compared to those of the control group, suggesting neurturin-induced growth of the dopaminergic axons. Striatal dopamine levels also significantly increased in the neurturin-treated rats compared with those in the control group of rats, accompanied by the recovery of methamphetamine-induced rotation in the neurturin-treated rats. In conclusion, an intrastriatal injection of neurturin is a useful method to protect nigral dopaminergic neurons from extensive cell death in a model of progressive Parkinson's disease, as well as to promote the axonal regeneration and dopaminergic function.
Similar articles
-
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.Eur J Neurosci. 1999 May;11(5):1554-66. doi: 10.1046/j.1460-9568.1999.00566.x. Eur J Neurosci. 1999. PMID: 10215908
-
Progressive and extensive dopaminergic degeneration induced by convection-enhanced delivery of 6-hydroxydopamine into the rat striatum: a novel rodent model of Parkinson disease.J Neurosurg. 2003 Jan;98(1):136-44. doi: 10.3171/jns.2003.98.1.0136. J Neurosurg. 2003. PMID: 12546362
-
Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease.Neuroscience. 2007 May 25;146(3):1245-58. doi: 10.1016/j.neuroscience.2007.02.004. Epub 2007 Mar 23. Neuroscience. 2007. PMID: 17363174
-
Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.Clin Exp Pharmacol Physiol. 2001 Nov;28(11):896-900. doi: 10.1046/j.1440-1681.2001.03544.x. Clin Exp Pharmacol Physiol. 2001. PMID: 11703392 Review.
-
Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.Brain Res. 2000 Dec 15;886(1-2):82-98. doi: 10.1016/s0006-8993(00)02915-2. Brain Res. 2000. PMID: 11119690 Review.
Cited by
-
Effect of cerebral dopamine neurotrophic factor on endogenous neural progenitor cell migration in a rat model of Parkinson's disease.EXCLI J. 2019 Mar 5;18:139-153. eCollection 2019. EXCLI J. 2019. PMID: 30956647 Free PMC article.
-
Challenges and promises in the development of neurotrophic factor-based therapies for Parkinson's disease.Drugs Aging. 2014 Apr;31(4):239-61. doi: 10.1007/s40266-014-0160-x. Drugs Aging. 2014. PMID: 24610720 Review.
-
Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.PLoS One. 2017 Jun 16;12(6):e0179476. doi: 10.1371/journal.pone.0179476. eCollection 2017. PLoS One. 2017. PMID: 28622392 Free PMC article.
-
Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.Mol Neurobiol. 2014 Oct;50(2):559-73. doi: 10.1007/s12035-014-8639-3. Epub 2014 Feb 7. Mol Neurobiol. 2014. PMID: 24504901 Review.
-
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain.Neuropharmacology. 2010 Jun;58(7):1114-21. doi: 10.1016/j.neuropharm.2010.02.002. Epub 2010 Feb 11. Neuropharmacology. 2010. PMID: 20153340 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases